HIGHLIGHTS
- who: Slovak Republik and collaborators from the Department of Oncology, Specialised Hospital of St Zoerardus Zobor, Nitra, Department of Oncology, Faculty of Medicine, Comenius University and StElisabeth Cancer Institute, Bratislava have published the research: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021; 165:XX, in the Journal: (JOURNAL)
SUMMARY
In first- and second-generation TKIs, the acquired resistance is mediated in about 60% of cases by the secondary EGFR mutation T790M. Other mechanisms are HER2 amplification, MET amplification, transformation into small-cell carcinoma (SCLC), epithelialto-mesenchymal transition (EMT), PIK3CA mutation, BRAF . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.